This document summarizes the results of five phases of testing ERCC control transcripts on Agilent microarrays to evaluate their performance. In Phase III, ERCC transcripts were spiked into background RNA at various dilutions. Analysis of probe performance at different distances from the 3' end showed good signals for probes >1000nt from the polyA tail. Phase IV constructed pools with ERCCs at different concentrations to test a wide dynamic range. Phase V experiments showed Agilent microarrays can detect small differences in ERCC levels used as barcodes to track samples. The ERCC controls helped evaluate the microarray process and different platforms.
Assessing Test Case Prioritization on Real Faults and MutantsKevin Moran
Test Case Prioritization (TCP) is an important component of regression testing, allowing for earlier detection of faults or helping to reduce testing time and cost. While several TCP approaches exist in the research literature, a growing number of studies have evaluated them against synthetic software defects, called mutants. Hence, it is currently unclear to what extent TCP performance on mutants would be representative of the performance achieved on real faults. To answer this fundamental question, we conduct the first empirical study comparing the performance of TCP techniques applied to both real-world and mutation faults. The context of our study includes eight well-studied TCP approaches, 35k+ mutation faults, and 357 real-world faults from five Java systems in the Defects4J dataset. Our results indicate that the relative performance of the studied TCP techniques on mutants may not strongly correlate with performance on real faults, depending upon attributes of the subject programs. This suggests that, in certain contexts, the best performing technique on a set of mutants may not be the best technique in practice when applied to real faults. We also illustrate that these correlations vary for mutants generated by different operators depending on whether chosen operators reflect typical faults of a subject program. This highlights the importance, particularly for TCP, of developing mutation operators tailored for specific program domains.
Determination of Oxygenates & BTX in Beverage Grade Carbon DioxideJennifer Maclachlan
In this paper, we describe a method for volatile oxygenates and demonstrate that it
can be combined with the previous BTX (1) method to perform multifunctional analyte
analyses. The photoionization detector (PID) has been improved to provide the sensitivity and
ppb detection limits required by the industry. The 301-B now has multiple valve switching
capability and multiple autozeros to smooth the baseline when columns are switched in or out.
With these changes and system optimizations, we have achieved some complex separations at
ppb levels with a minimum of operator time or training required.
The following method on the 301-B was developed for the analysis of ppb levels of oxygenates
(acetaldehyde, methanol & dimethyl ether) in beverage grade carbon dioxide. The detection
limits required were 100 ppb for acetaldehyde and dimethyl ether.
The analysis can be automated via a PLC that controls the 301-B (start, calibrate, print report).
An optional operating system is Windows XP. If the 301 GC is part of the plant network, the
system can be operated from any PC on the network. Of course the system has passwords.
The detection limit for this analysis was <100 ppb (acetaldehyde), & <50 ppb (dimethyl
ether) for a direct injection with no concentration of the sample. The analysis time for this
multicomponent analysis was < 10 minutes.
Assessing Test Case Prioritization on Real Faults and MutantsKevin Moran
Test Case Prioritization (TCP) is an important component of regression testing, allowing for earlier detection of faults or helping to reduce testing time and cost. While several TCP approaches exist in the research literature, a growing number of studies have evaluated them against synthetic software defects, called mutants. Hence, it is currently unclear to what extent TCP performance on mutants would be representative of the performance achieved on real faults. To answer this fundamental question, we conduct the first empirical study comparing the performance of TCP techniques applied to both real-world and mutation faults. The context of our study includes eight well-studied TCP approaches, 35k+ mutation faults, and 357 real-world faults from five Java systems in the Defects4J dataset. Our results indicate that the relative performance of the studied TCP techniques on mutants may not strongly correlate with performance on real faults, depending upon attributes of the subject programs. This suggests that, in certain contexts, the best performing technique on a set of mutants may not be the best technique in practice when applied to real faults. We also illustrate that these correlations vary for mutants generated by different operators depending on whether chosen operators reflect typical faults of a subject program. This highlights the importance, particularly for TCP, of developing mutation operators tailored for specific program domains.
Determination of Oxygenates & BTX in Beverage Grade Carbon DioxideJennifer Maclachlan
In this paper, we describe a method for volatile oxygenates and demonstrate that it
can be combined with the previous BTX (1) method to perform multifunctional analyte
analyses. The photoionization detector (PID) has been improved to provide the sensitivity and
ppb detection limits required by the industry. The 301-B now has multiple valve switching
capability and multiple autozeros to smooth the baseline when columns are switched in or out.
With these changes and system optimizations, we have achieved some complex separations at
ppb levels with a minimum of operator time or training required.
The following method on the 301-B was developed for the analysis of ppb levels of oxygenates
(acetaldehyde, methanol & dimethyl ether) in beverage grade carbon dioxide. The detection
limits required were 100 ppb for acetaldehyde and dimethyl ether.
The analysis can be automated via a PLC that controls the 301-B (start, calibrate, print report).
An optional operating system is Windows XP. If the 301 GC is part of the plant network, the
system can be operated from any PC on the network. Of course the system has passwords.
The detection limit for this analysis was <100 ppb (acetaldehyde), & <50 ppb (dimethyl
ether) for a direct injection with no concentration of the sample. The analysis time for this
multicomponent analysis was < 10 minutes.
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...Thermo Fisher Scientific
The introduction of defined Ion AmpliSeq™ panels for detection and characterization of actionable mutations occurring in tumor tissue has the potential to revolutionize translational oncology research. The Ion Ampliseq™ cancer hot spot panel version 2 (CHP v2) by Ion Torrent includes 207 actionable sequences from a single target and mutation targets present in 50 genes and the more comprehensive Ion Oncomine™ cancer panel (OCP) developed by Life Technologies Compendia Bioscience™ contains over 2000 mutations. A hallmark of these Ion Torrent Ampliseq cancer panels is the low amount of input DNA needed which is critical when the clinical specimen material is limited such as with fine needle biopsy or FFPE samples. Typically, 10 ng of DNA obtained from these sources is sufficient to produce informative sequencing data. Often, cancer-causing or promoting mutations are detected at relatively low allele frequencies like 10-20 % compared to the major normal allele. Many researchers wish to verify these findings of low frequency mutations by an orthologous method such as traditional dye-fluorescent Sanger sequencing on a capillary electrophoresis (CE) instrument such as the Applied Biosystems 3500 genetic analyzer. To that end, we have developed a workflow that enables the amplification and traditional Sanger sequencing of individual Ion AmpliSeq targets directly from the AmpliSeq library starting material.
The method requires a retainer of 1 μl (~ 5%) of the original AmpliSeq preamplification material. A dilution of this aliquot is used as template source for individualized PCR/sequencing reactions. We show that a random selection of 48 targets from the CHPv2 panel could be successfully amplified and Sanger-sequenced from an Ion Torrent Ampliseq library originally prepared from 10 ng of FFPE
DNA. Furthermore, we show the successful Sanger-re-sequencing of all individual 24 targets covering the TP53 exons from the same sample processed and pre-amplified with the OncoMine AmpliSeq panel.
Taken together, this method will enable researchers to reflex-test potential mutations of interest from very material-limited specimen using Sanger CE sequencing
While Phosphorous (31P) MRS (I) has been promising in experimental and clinical settings since the early 70s, it has been beset by prohibitively lower sensitivity, limited spectral-spatial resolution, and prolonged acquisition. This manuscript and proceedings of the annual scientific meeting of ISMRM in 2022 (REF1) and 2023 (REF2) demonstrate that our novel acquisition strategy, the novel Rosette Trajectory for fast and flexible MR(S)I contrast (Shen et al. 2023 (REF3), later we renamed it as PETALUTE after the translation to the preclinical scanners of 7T and 9.4T), enables operator-independent (1) rapid acquisition (~7 minutes), (2) reconstruction, and (3) processing pipeline, resulting in phosphorous metabolite ratio maps (10 x 10 x 10 mm3) of the whole brain.
In response to the “Repeat it with Me” challenge organized by the Reproducible Research study group of ISMRM, we demonstrated the power of this technique in 5 healthy volunteers at three different institutions with different experimental setups (2nd Place: UTE 31P 3D Rosette MRSI Reproducibility Team, REF4). Since the proposed acquisition/reconstruction/processing pipeline was operator/scanner/coil-independent, the Reproducer sub-teams successfully replicated the findings of the original proceeding in 2022 (REF1). As part of this challenge, we provided some MATLAB scripts and k-space data to reproduce some of the results described in this manuscript. The software and data can be downloaded from https://purr.purdue.edu/projects/ismrm31pmrsi.
These results will likely be of broad interest across clinical settings since the proposed acquisition strategy is not specific to any region, nuclei, or magnetic field and is operator-independent. This study's resolution and signal-to-noise ratios permit the metabolite maps in an experimentally and clinically feasible timeframe at 3 Tesla and 7T.
REF1 Bozymski B, Shen X, Ozen AC, Ibey S, Chiew M, Thomas A, Dydak U, Emir UE. Ultra-Short Echo Time 31P 3D MRSI at 3T with Novel Rosette k-space Trajectory. Proceedings 30th Scientific Meeting, International Society for Magnetic Resonance in Medicine, 2022.
REF2 Farley N, Bozymski B, Dydak U, Emir UE*. Fast 3D 31P MRSI Using Novel Rosette Petal Trajectory at 3T with x4 Accelerated Compressed Sensing. Proceedings 31st Scientific Meeting, International Society for Magnetic Resonance in Medicine, 2023.
REF3 Shen X, Özen AC, Sunjar A, Ilbey S, Sawiak S, Shi R, Chiew M, Emir UE. Ultrashort T2 components imaging of the whole brain using 3D dual-echo UTE MRI with rosette k-space pattern. Magnetic Resonance in Medicine. 2023;89(2):508–521.
REF4 https://challenge.ismrm.org/2023-24-reproducibility-challenge/results-22-23/
Technical Guide to Qiagen PCR Arrays - Download the GuideQIAGEN
Total RNA discovery with RT2 and miScript PCR Arrays : Explore the RNA universe - Whatever your destination within the RNA universe, QIAGEN will help you get there. The miRNeasy kits deliver pure, high-quality total RNA from a broad range of samples. The RT2 and miScript PCR arrays are a complete solution both for focused analysis of gene and microRNA expression and for validation of microarray and RNA sequencing experiments. Together with the powerful analytics tools of GeneGlobe® and QIAGEN Ingenuity® Pathway Analysis, these products give you a smooth path from your sample to high-quality results.
Direct Sanger CE Sequencing of Individual Ampliseq Cancer Panel Targets from ...Thermo Fisher Scientific
The introduction of defined Ion AmpliSeq™ panels for detection and characterization of actionable mutations occurring in tumor tissue has the potential to revolutionize translational oncology research. The Ion Ampliseq™ cancer hot spot panel version 2 (CHP v2) by Ion Torrent includes 207 actionable sequences from a single target and mutation targets present in 50 genes and the more comprehensive Ion Oncomine™ cancer panel (OCP) developed by Life Technologies Compendia Bioscience™ contains over 2000 mutations. A hallmark of these Ion Torrent Ampliseq cancer panels is the low amount of input DNA needed which is critical when the clinical specimen material is limited such as with fine needle biopsy or FFPE samples. Typically, 10 ng of DNA obtained from these sources is sufficient to produce informative sequencing data. Often, cancer-causing or promoting mutations are detected at relatively low allele frequencies like 10-20 % compared to the major normal allele. Many researchers wish to verify these findings of low frequency mutations by an orthologous method such as traditional dye-fluorescent Sanger sequencing on a capillary electrophoresis (CE) instrument such as the Applied Biosystems 3500 genetic analyzer. To that end, we have developed a workflow that enables the amplification and traditional Sanger sequencing of individual Ion AmpliSeq targets directly from the AmpliSeq library starting material.
The method requires a retainer of 1 μl (~ 5%) of the original AmpliSeq preamplification material. A dilution of this aliquot is used as template source for individualized PCR/sequencing reactions. We show that a random selection of 48 targets from the CHPv2 panel could be successfully amplified and Sanger-sequenced from an Ion Torrent Ampliseq library originally prepared from 10 ng of FFPE
DNA. Furthermore, we show the successful Sanger-re-sequencing of all individual 24 targets covering the TP53 exons from the same sample processed and pre-amplified with the OncoMine AmpliSeq panel.
Taken together, this method will enable researchers to reflex-test potential mutations of interest from very material-limited specimen using Sanger CE sequencing
While Phosphorous (31P) MRS (I) has been promising in experimental and clinical settings since the early 70s, it has been beset by prohibitively lower sensitivity, limited spectral-spatial resolution, and prolonged acquisition. This manuscript and proceedings of the annual scientific meeting of ISMRM in 2022 (REF1) and 2023 (REF2) demonstrate that our novel acquisition strategy, the novel Rosette Trajectory for fast and flexible MR(S)I contrast (Shen et al. 2023 (REF3), later we renamed it as PETALUTE after the translation to the preclinical scanners of 7T and 9.4T), enables operator-independent (1) rapid acquisition (~7 minutes), (2) reconstruction, and (3) processing pipeline, resulting in phosphorous metabolite ratio maps (10 x 10 x 10 mm3) of the whole brain.
In response to the “Repeat it with Me” challenge organized by the Reproducible Research study group of ISMRM, we demonstrated the power of this technique in 5 healthy volunteers at three different institutions with different experimental setups (2nd Place: UTE 31P 3D Rosette MRSI Reproducibility Team, REF4). Since the proposed acquisition/reconstruction/processing pipeline was operator/scanner/coil-independent, the Reproducer sub-teams successfully replicated the findings of the original proceeding in 2022 (REF1). As part of this challenge, we provided some MATLAB scripts and k-space data to reproduce some of the results described in this manuscript. The software and data can be downloaded from https://purr.purdue.edu/projects/ismrm31pmrsi.
These results will likely be of broad interest across clinical settings since the proposed acquisition strategy is not specific to any region, nuclei, or magnetic field and is operator-independent. This study's resolution and signal-to-noise ratios permit the metabolite maps in an experimentally and clinically feasible timeframe at 3 Tesla and 7T.
REF1 Bozymski B, Shen X, Ozen AC, Ibey S, Chiew M, Thomas A, Dydak U, Emir UE. Ultra-Short Echo Time 31P 3D MRSI at 3T with Novel Rosette k-space Trajectory. Proceedings 30th Scientific Meeting, International Society for Magnetic Resonance in Medicine, 2022.
REF2 Farley N, Bozymski B, Dydak U, Emir UE*. Fast 3D 31P MRSI Using Novel Rosette Petal Trajectory at 3T with x4 Accelerated Compressed Sensing. Proceedings 31st Scientific Meeting, International Society for Magnetic Resonance in Medicine, 2023.
REF3 Shen X, Özen AC, Sunjar A, Ilbey S, Sawiak S, Shi R, Chiew M, Emir UE. Ultrashort T2 components imaging of the whole brain using 3D dual-echo UTE MRI with rosette k-space pattern. Magnetic Resonance in Medicine. 2023;89(2):508–521.
REF4 https://challenge.ismrm.org/2023-24-reproducibility-challenge/results-22-23/
Technical Guide to Qiagen PCR Arrays - Download the GuideQIAGEN
Total RNA discovery with RT2 and miScript PCR Arrays : Explore the RNA universe - Whatever your destination within the RNA universe, QIAGEN will help you get there. The miRNeasy kits deliver pure, high-quality total RNA from a broad range of samples. The RT2 and miScript PCR arrays are a complete solution both for focused analysis of gene and microRNA expression and for validation of microarray and RNA sequencing experiments. Together with the powerful analytics tools of GeneGlobe® and QIAGEN Ingenuity® Pathway Analysis, these products give you a smooth path from your sample to high-quality results.
Detection of somatic mutations at 0.5% frequency from cfDNA and CTC DNA using...Thermo Fisher Scientific
Availability of effective blood screening for tracking of recurrence and
resistance of tumors may improve outcomes in the future. Research
studies suggest that virtually all tumors carry somatic DNA mutations, and
these may serve as biomarkers that may be tracked from blood. The
two well-characterized sources of tumor DNA in blood are circulating
tumor cells (CTC) and cell-free tumor DNA (ctDNA). The abundance of
CTC and/or ctDNA in blood may be very low at critical stages such as
early recurrence or development of resistance. Hence there is great
interest in being able to detect biomarkers at very low frequency from
blood, and in characterizing the relationship between somatic mutations
present in the tumor and those in CTC or ctDNA.
We present a research use only analysis workflow for peripheral
monitoring that enables detection of low frequency variants in blood. We
developed an analysis algorithm, using statistical modeling of next
generation sequencing reads, and optimizing parameters and filters to
enable sensitive and specific detection of somatic mutations at 0.5% allele
ratio. We demonstrate the analysis on a blood sample split into 3 subsamples
comprising normal blood, CTC enriched, and cell-free DNA
(cfDNA) samples.
We used lysis to isolate white blood cells (germline), centrifugation to
extract plasma DNA (cfDNA), while CTC cells were isolated using
Cynvenio LiquidBiopsy™ platform a fully automated antibody-based
solution. We barcoded 3 sub-samples and run them on a single Ion 318™
sequencing chip using Ion AmpliSeq™ Cancer Hotspot Panel (CHPv2),
that enables very deep (~10,000x coverage) and accurate
sequencing. This panel allows interrogation of ~2800 relevant
biomarkers from COSMIC and FDA actionable databases, and denovo
variant detection at ~20,000 genomic positions. Mutations were
annotated using the Oncomine® database in Ion Reporter™ software. The
research assay requires a small amount of input DNA (~10ng), and has a
fast turn around time from extracted DNA to variants of less than 24 hr.
A rapid library preparation method with custom assay designs for detection of...Thermo Fisher Scientific
Herein, we describe a new research method for library
preparation using the Ion AmpliSeq™ HD Library Kit with
custom assay designs from Ion AmpliSeq HD Panels for
detection of low level variants from liquid biopsy samples. This
method includes incorporation of molecular tags that enable
0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and
dual barcodes for sample identification. This method is also
applicable to formalin-fixed paraffin embedded (FFPE)
samples. The libraries can be prepared in as little as 3 hours
and are compatible for analysis with the Ion GeneStudio™ S5
system
Similar to 20140710 4 a_bergstrom_lucas_ercc2.0_workshop (20)
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Astronomy Update- Curiosity’s exploration of Mars _ Local Briefs _ leadertele...
20140710 4 a_bergstrom_lucas_ercc2.0_workshop
1. ERCC Transcripts Provide
Confidence to the
Performance of Agilent
One-Color and Two-Color
Microarray Experiments
Anne Bergstrom Lucas
Senior Research Scientist
July 10th 2014
2. Overview
- Quick review of ERCC Phases
- Agilent microarray probe generation and assay overview
- Questions regarding the dilution of the ERCC transcript pools
- Probe/ERCC performance in Phase III (latin-square proof-of-concept)
- Probe/ERCC performance in Phase IV (functional testing)
- Probe/ERCC performance in Phase V (external validation)
- Conclusions
7/10/2014
ERCC 2.0 Workshop
2
3. Number of ERCC clones
177
144
106
97
96
The Five Phases of ERCC Control Testing
BMC Genomics 2005, 6:150
7/10/2014
ERCC 2.0 Workshop
3
4. ERCC Control Transcripts Test Entire Assay
Spike-in controls for Validation
External, Exogenous
Sequences that do not
naturally appear in sample
Synthetic
Known [RNA]
traceable to SI
Known Sequence
traceable to reference
library RM
Track “whole-system” technical
performance
RNA
Isolation
Target
Preparation
optional mRNA
Amplification
Hybridization
Array
Content
Hybridized
Target
Detection
Expression
Measures
Biostatistical
Analysis
Spike-ins
to track
whole-
process
7/10/2014
ERCC 2.0 Workshop
4
5. ERCC transcripts were uploaded into the Agilent eArray program:
• Ran probe selection program using two different modes:
- “Best Probe”
- “Best Distribution”
Combined the lists from each mode to give ten probes that span each control sequence up to
>1000 bases from the 3’ end
- Two copies of each of the ten probes were ported into the 8x15K microarray format
- The rest of the space was filled with human biological genes from the catalog array
Used eArray Program for ERCC Microarray Probe Design
AAAAAAAA
7/10/2014
ERCC 2.0 Workshop
5
6. Amp and Labeling Experimental Setup
Used Agilent’s Low Input Linear RNA Amplification Kit (LILAK) for Phases II
and III and the Agilent Low Input QuickAmp Kit for Phase IV
Background RNA was Ambion Human Liver Reference and the LIQA reactions
had an input of 10 ng total RNA per reaction for Phase IV
All labeling reactions were performed in triplicate and hybridized as
amp/labeling technical replicates
The Cy3 amp and labeling reactions are doing double duty as One-Color
targets and Two-Color targets
7/10/2014
ERCC 2.0 Workshop
6
7. Agilent Microarray Data Analysis
• Concentrated on the “Processed Signals”
• Scanner offset is subtracted
• Background is subtracted
• Multiplicative detrend signal (maybe)
• 75th Percentile scaling across arrays
• Filtered/omitted data from “Non-Uniform” probes
• Wanted to retain the probes that were saturated
• Also wanted to retain the probes were hard to detect
• Analyzed the data for the 10 different ERCC probes to select a single
probe per ERCC transcript for inclusion on every the control grid on
Agilent commercial gene expression microarray format
7/10/2014
ERCC 2.0 Workshop
7
9. Suggested Concentrations of Pools for Modified Latin Square
Experiments (Dilution 1) in ERCC Phase III
Note that concentrations are based on ratios of
the mass of the spike-in RNA transcript to the
mass of background total RNA (based on the
assumptions of an average transcript length of
1000 bases, etc.)
7/10/2014
ERCC 2.0 Workshop
9
10. Further Suggested Dilutions for Expanded Range Experiments for
Modified Latin Square Experiments (Dilution 1) in ERCC Phase III
Suggested
Dilution 2 is 1:2
Suggested
Dilution 3 is 1:4
Suggested
Dilution 4 is 1:40
7/10/2014
ERCC 2.0 Workshop
10
We wanted (and needed) higher dilutions for the Agilent microarray platform!
11. Comparing Phase III ERCC Spike-In Dilutions to the Agilent
Spike-In Control Dilutions (mass of ERC per mass of total RNA)
1:12,500
1:37,500
1:125,000
1:375,000
1:1,250,000
1:3,750,000
1:12,500,000
1:125,000,000
1:1,250,000,000
1:12,500,000,000
1:1,000
1:5,000
1:25,000
1:125,000
1:10,000,000
1:50,000,000
1:250,000,000
1:1,250,000,000
1:100,000
1:500,000
1:2,500,000
1:12,500,000
Suggested
Dilutions
100-Fold
Dilutions that
hit Agilent’s
“Sweet Spot”
10,000-Fold
Dilutions that
test the limits of
diluting the
ERCC Spike-Ins
7/10/2014
ERCC 2.0 Workshop
11
12. Example of ERCC Performance in Phase III
For the control ERCC-00061
Log2gProcessedSignals
Log2 Mass Spiked
Pools Diluted 1:10,000 Pools Diluted 1:100 Pools Diluted as Described
7/10/2014
ERCC 2.0 Workshop
12
13. Can Combine 1-C Data to Test Full Dynamic Range
For the control ERCC-00061
Log2 Mass Spiked
Log2gProcessedSignals
7/10/2014
ERCC 2.0 Workshop
13
14. Microarray Data Indicated Some ERCCs Didn’t Dilute As Expected…
ERCC-00073 Was Added to Pool 9 at Wrong Concentration?
Log2gProcessedSignals
Log2 Mass Spiked
7/10/2014
ERCC 2.0 Workshop
14
15. Does Distance From 3’ End Make a Difference in Probe Performance?
Distance to the 3’ end of the ERCC on the X-axis
Versus Log2 gProcessed Signals (Or Log10 Ratios) on the Y-axis
Log2gProcessedSignals
Distance (nt) to 3’ End of ERC
7/10/2014
ERCC 2.0 Workshop
15
16. Example ERCC Probes That Gave Expected 1-Color Array Signals
For the control ERCC-00028
Pool 10
Pool 9
Pool 8
Pool 7
Liver Control
Log2gProcessedSignals
Distance (nt) to 3’ End of ERC
7/10/2014
ERCC 2.0 Workshop
16
Signals between pools for a given probe
differ 5-fold as expected from the dilutions
Don’t want to select a probe that gives
significant signal in the control sample
17. Example ERCC Probes That Gave Expected 2-Color Array Log10 Ratios
For the same control ERCC-00028
Log10Ratios
Distance (nt) to 3’ End of ERC
7/10/2014
ERCC 2.0 Workshop
17
Crosshyb signal from background RNA
results in compressed log ratios …note that
amount of compression observed is sensitive
to amount of ERCC spiked into the mixture
Good log ratio correlations for microarray
probes located >1000 nt from polyA+ tail
19. Construction of the ERCC Phase IV Pools
Each of the 97 ERCC RNA transcripts were diluted to make up 5 different pools
(Pool A through Pool E)
Fewer ERCC spike-in controls were placed at the top end of the dynamic range so
the sample prep reagents would not be swamped by the ERCC spike-in controls
7/10/2014
ERCC 2.0 Workshop
19
20. Mixing Sub-Pools at Different Concentrations to Obtain Mixtures 1 to 4
Sub-Pools A thru D were present
at one of 4 concentrations in
each final pool: 40%, 25%,
15%, and 10%
Sub-Pool E was held at a constant
concentration of 10% across all
of the final pools
Comparing ratios across the final
pools test ratios from 1x, 1.5x,
1.6x, 1.7x, 2.5x, 2.7x, and 4x
7/10/2014
ERCC 2.0 Workshop
20
21. Agilent Phase IV One-Color “Gummy Worm” Plots
Lower limit of
detection
Saturation
7/10/2014
ERCC 2.0 Workshop
21
22. Agilent Phase IV
One-Color Plots
Plus “Gummy” Slope Values
Many of the ERCC
controls have
slopes at or
near 1
7/10/2014
ERCC 2.0 Workshop
22
23. Making “Gummy Worm” Plots with Agilent 2-Color Data
Can you use the
average of the
green and red
signals from the
2-color “self-self”
arrays?
Yes!
7/10/2014
ERCC 2.0 Workshop
23
24. How Do Observed Ratios
Compare to Signal Intensities?
Example: Mix 1 vs. Mix 2
Log2
Ratio
0.68
0.74
0.58
-2.0
0.0 10%
40%
10%
15%
25%
Log2 Signals are on the X-axis
Log2 Ratios are on the Y-Axis
7/10/2014
ERCC 2.0 Workshop
24
25. Agilent One-Color
Observed Log Ratio
Versus Signal Data
Across All Six Possible
Mixture Combinations
In general the Agilent
One-Color Microarray
platform does a great job
of measuring ratios that
are very close to the
expected ratios across a
wide dynamic range!
7/10/2014
ERCC 2.0 Workshop
25
26. Agilent
One-Color vs.
Two-Color
Performance
Difference in
saturation levels
likely due to
differences in
the amount of
labeled target
loaded per color
channel
(2x higher for
Agilent One-Color)
One-Color Two-Color
7/10/2014
ERCC 2.0 Workshop
26
28. Example of Agilent Performance in ERCC Phase V Experiments
The Allen Institute for Brain Science has built a “Human Brain Atlas”
which includes gene expression, histological, and MRI data from
several individual post-mortem brains
In phase 1 of this project this project they sectioned the human brains
into ~1,000 parts and analyzed gene expression in each of the 1,000
different areas on Agilent One-Color 8x60K microarrays
The Allen Institute used 20 of the ERCC controls transcripts in a
“barcode” fashion to keep track of samples from a 96-well plate format
The Allen Institute had a control specific for each row and each column of
the 96-well plate to create a specific two ERCC control “barcode” for
each of the 96 possible row-column positions in the plate
7/10/2014
ERCC 2.0 Workshop
28
29. Phase V “Barcoding” Experiment Illustrated
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
7/10/2014
ERCC 2.0 Workshop
29
30. Conclusions
We were able to successfully design 60-mer probes corresponding to each of the
ERCC transcripts and demonstrate robust measurements with IVT labeling
Every Agilent gene expression microarray control grid contains probes to the each
of the 96 ERCC transcripts (replicated 10x on the 8x60K platform)
Agilent and other measurement platforms were sensitive enough to detect
anomalies in the construction of the ERCC test pools
ERCC transcripts diluted in range of 220 demonstrate that microarrays are capable
of detecting gene expression differences spanning over 5 orders of magnitude
The ERCC transcripts help to explore the differences between the one-color and
two-color microarray data
Agilent customers such as the Allen Brain Institute have successfully used the
ERCC controls for sample tracking in their microarray experiments
7/10/2014
ERCC 2.0 Workshop
30
31. Thank You!
Agilent:
• Paul Wolber
• Marc Visitacion
• Gary Lin
ERCC 1.0 Phase IV Core Team:
• Marc Salit
• Scott Pine
• Jean Lozach
• Tim Myers
• Sarah Jacob-Helber
• Jenny McDaniel
• Sarah Munro
7/10/2014
ERCC 2.0 Workshop
31
32. Stay Tuned Tomorrow…
Joel Myerson (Agilent) Talk Friday
“Efficient Chemical Synthesis of Long and Modified RNA Oligonucleotides”
7/10/2014
ERCC 2.0 Workshop
32
34. Visual Effects of ERCC Spike-In Concentrations
Cy5 Pool 10 + Cy3 Pool 8 Liver Control (no ERCs)
Cy5 Pool 10 + Cy3 Pool 10Cy5 Pool 8 + Cy3 Pool 10
7/10/2014
ERCC 2.0 Workshop
34